Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 2-stage, Phase 2a Study to Evaluate the Efficacy, Safety, and Tolerability of OLP-1002 Subcutaneous Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in a Hip and/or Knee Joint

NCT05216341 is registered in ClinicalTrials.gov with OliPass Corporation as lead sponsor.

NCT NCT05216341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05216341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 2-stage, Phase 2a Study to Evaluate the Efficacy, Safety, and Tolerability of OLP-1002 Subcutaneous Injections for Reducing Moderate to Severe Pain Due to Osteoarthritis in a Hip and/or Knee Joint
Lead sponsor
OliPass Corporation
Phase
Phase 2
Overall status
Completed
Start date
January 11, 2021
Completion date
September 7, 2023
Enrollment
134 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

osteoarthritis